TY - JOUR
T1 - Premature and early menopause among US women with or at risk for HIV
AU - Bullington, Brooke W.
AU - Edmonds, Andrew
AU - Ramirez, Catalina
AU - Rahangdale, Lisa
AU - Neal-Perry, Genevieve
AU - Konkle-Parker, Deborah
AU - Weiss, Deborah Jones
AU - Moran, Caitlin
AU - Golub, Elizabeth Topper
AU - Cejtin, Helen
AU - Seidman, Dominika
AU - Kassaye, Seble
AU - Wilson, Tracey E.
AU - Sharma, Anjali
AU - Adimora, Adaora A.
AU - Knittel, Andrea K.
N1 - Publisher Copyright:
© 2022 Lippincott Williams and Wilkins. All rights reserved.
PY - 2022/6/14
Y1 - 2022/6/14
N2 - Objective:Little is known about the prevalence and treatment of premature and early menopause among people with HIV. We described premature and early menopause and subsequent hormonal treatment in a longitudinal cohort of women living with or at risk for HIV in the US.Methods:Data from the Women's Interagency HIV Study between 2008 and 2020 were analyzed to describe premature and early menopause among cohort participants under the age of 51.Results:Of 3,059 eligible women during the study period, 1% (n=35) underwent premature menopause before age 41, 3% (n=101) underwent menopause between ages 41 and 46, and 21% (n=442) underwent menopause between ages 46 and 50, inclusive. Of participants who experienced menopause before age 41, between age 41 and 45, and between ages 46 and 50, 51%, 24%, and 7% (respectively) received either menopausal hormone therapy or hormonal contraception.Conclusion:These findings suggest that disparities in receipt of recommended hormone therapy for premature and early menopause may contribute, in part, to evident health disparities, such as cardiovascular disease, osteoporosis, and overall mortality. They also suggest a substantial need for education among people experiencing early menopause and their providers, with the goal of improving access to hormone therapy based on guidelines to address health disparities and minimize future health consequences.
AB - Objective:Little is known about the prevalence and treatment of premature and early menopause among people with HIV. We described premature and early menopause and subsequent hormonal treatment in a longitudinal cohort of women living with or at risk for HIV in the US.Methods:Data from the Women's Interagency HIV Study between 2008 and 2020 were analyzed to describe premature and early menopause among cohort participants under the age of 51.Results:Of 3,059 eligible women during the study period, 1% (n=35) underwent premature menopause before age 41, 3% (n=101) underwent menopause between ages 41 and 46, and 21% (n=442) underwent menopause between ages 46 and 50, inclusive. Of participants who experienced menopause before age 41, between age 41 and 45, and between ages 46 and 50, 51%, 24%, and 7% (respectively) received either menopausal hormone therapy or hormonal contraception.Conclusion:These findings suggest that disparities in receipt of recommended hormone therapy for premature and early menopause may contribute, in part, to evident health disparities, such as cardiovascular disease, osteoporosis, and overall mortality. They also suggest a substantial need for education among people experiencing early menopause and their providers, with the goal of improving access to hormone therapy based on guidelines to address health disparities and minimize future health consequences.
KW - Early menopause
KW - HIV
KW - Menopausal hormone therapy
KW - Premature menopause
UR - http://www.scopus.com/inward/record.url?scp=85131771341&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85131771341&partnerID=8YFLogxK
U2 - 10.1097/GME.0000000000001964
DO - 10.1097/GME.0000000000001964
M3 - Article
C2 - 35324546
AN - SCOPUS:85131771341
SN - 1072-3714
VL - 29
SP - 741
EP - 747
JO - Menopause
JF - Menopause
IS - 6
ER -